Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...
Icelandic biosimilar company Alvotech and Israeli drugmaker Teva Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application ...
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback